EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Affinity Selection of MS2 VLPs as SARS-CoV-2 Vaccine Candidates Targeting Nucleocapsid Protein

Julianne Peabody iD, Chunyan Ye, Steven Bradfute iD, Bryce Chackerian iD, David S Peabody iD

Viruses · 13.07.2026 · 18 (7) · 766

DOI: 10.3390/v18070766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 13.07.2026. Verfasst von Julianne Peabody und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA. Hauptthemen laut MEDLINE: Vaccines, Virus-Like Particle, COVID-19, SARS-CoV-2, Levivirus. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying antigens that elicit protective immunity is the key step for vaccine development. Here, we describe the use of the MS2 VLP platform to identify epitopes of SARS-CoV-2 structural proteins recognized by antibodies from COVID-19 patients, and to present those epitopes to the immune system as vaccines. We constructed an MS2 virus-like particle (VLP) library covering all four structural proteins of SARS-CoV-2 and affinity-selected vaccine candidates by biopanning on antibodies from infected humans. We focused on the structural proteins, reasoning that they are the most likely targets of a protective antibody response. The epitopes we found map almost entirely to the spike and nucleocapsid proteins. The VLPs displaying such epitopes were produced individually in E. coli and then tested for their potential as vaccines. While none of the affinity-selected spike-specific VLPs elicited neutralizing antibodies, VLPs displaying nucleocapsid epitopes induced protective immunity in a hamster model. This work illustrates the MS2 VLP platform’s capacity for the identification of new vaccine candidates and raises the possibility that VLPs displaying nucleocapsid epitopes could provide long-lasting protection against a range of virus variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, Virus-Like ParticleCOVID-19SARS-CoV-2LevivirusCOVID-19 VaccinesNucleocapsid ProteinsCoronavirus Nucleocapsid ProteinsAnimalsAntibodies, ViralHumansSpike Glycoprotein, CoronavirusEpitopesAntibodies, NeutralizingCricetinae

Stichwörter der Autor:innen

COVID-19 vaccinesMS2 VLPaffinity-selectionnucleocapsid protein

Substanzen

Vaccines, Virus-Like ParticleAntibodies, ViralCOVID-19 VaccinesSpike Glycoprotein, CoronavirusEpitopesAntibodies, NeutralizingNucleocapsid Proteinsspike protein, SARS-CoV-2Coronavirus Nucleocapsid Proteins

Autor:innen und Institutionen

  • Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
  • Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.

ORCID-Profile: Julianne Peabody, Steven Bradfute, Bryce Chackerian, David S Peabody

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • NIH
  • Research Allocations Committee of the University of New Mexico School of Medicine

Zitieren

APA

Peabody, J., Ye, C., Bradfute, S., Chackerian, B., & Peabody, D. S. (2026). Affinity Selection of MS2 VLPs as SARS-CoV-2 Vaccine Candidates Targeting Nucleocapsid Protein. Viruses, 18(7), 766. https://doi.org/10.3390/v18070766

Vancouver

Peabody J, Ye C, Bradfute S, Chackerian B, Peabody DS. Affinity Selection of MS2 VLPs as SARS-CoV-2 Vaccine Candidates Targeting Nucleocapsid Protein. Viruses. 2026;18(7):766. doi:10.3390/v18070766

BibTeX
@article{Peabody2026,
  author = {Peabody, Julianne and Ye, Chunyan and Bradfute, Steven and Chackerian, Bryce and Peabody, David S},
  title = {Affinity Selection of MS2 VLPs as SARS-CoV-2 Vaccine Candidates Targeting Nucleocapsid Protein},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {766},
  doi = {10.3390/v18070766}
}
Kostenlos starten →